Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
FcRn Antibody Fragment Submitted To US FDA In January
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
